NASDAQ : HRMY
Harmony Biosciences Holdings, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 38.59 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 2.25B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 2.26B |
| Enterprise Value | 1.75B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 4, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 58.24M |
| Shares Outstanding | 58.24M |
| Shares Change (YoY) | +0.65% |
| Shares Change (QoQ) | -0.04% |
| Owned by Insiders (%) | 0.11% |
| Owned by Institutions (%) | 98.36% |
| Float | 52.10M |
Ratios
| Measure | Value |
|---|
| PE Ratio | 12.54 |
| Forward PE | 9.76 |
| PS Ratio | 2.35 |
| Forward PS | 2.05 |
| PB Ratio | 2.25 |
| P/TBV Ratio | 2.45 |
| P/FCF Ratio | 6.36 |
| P/OCF Ratio | 6.36 |
| PEG Ratio | 0.29 |
Evratios
| Measure | Value |
|---|
| EV / Earnings | 9.65 |
| EV / Sales | 1.82 |
| EV / EBITDA | 6.83 |
| EV / EBIT | 7.59 |
| EV / FCF | 4.93 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 3.48 |
| Quick Ratio | 3.33 |
| Debt / Equity | 0.16 |
| Debt / EBITDA | 0.62 |
| Debt / FCF | 0.45 |
| Interest Coverage | 17.12 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | 20.46% |
| Return on Assets (ROA) | 11.62% |
| Return on Invested Capital (ROIC) | 37.45% |
| Return on Capital Employed (ROCE) | 20.25% |
| Weighted Average Cost of Capital (WACC) | 9.57% |
| Revenue Per Employee | $3.28M |
| Profits Per Employee | $618,669 |
| Employee Count | 293 |
| Asset Turnover | 0.77 |
| Inventory Turnover | 37.87 |
Taxes
| Measure | Value |
|---|
| Income Tax | 59.93M |
| Effective Tax Rate | 24.85% |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.01 |
| 52-Week Price Change | +32.20% |
| 50-Day Moving Average | 39.76 |
| 200-Day Moving Average | 34.69 |
| Relative Strength Index (RSI) | 51.06 |
| Average Volume (20 Days) | 1,043,289 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 5.41M |
| Short Previous Month | 5.53M |
| Short % of Shares Out | 9.30% |
| Short % of Float | 10.39% |
| Short Ratio (days to cover) | 5.33 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 959.90M |
| Gross Profit | 723.99M |
| Operating Income | 230.65M |
| Pretax Income | 241.20M |
| Net Income | 181.27M |
| EBITDA | 255.99M |
| EBIT | 230.65M |
| Earnings Per Share (EPS) | $3.09 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 667.79M |
| Total Debt | 160.19M |
| Net Cash | 507.60M |
| Net Cash Per Share | $8.72 |
| Equity (Book Value) | 999.24M |
| Book Value Per Share | 17.19 |
| Working Capital | 580.26M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 355.08M |
| Capital Expenditures | -178,000 |
| Depreciation & Amortization | 25.34M |
| Net Borrowing | -18.75M |
| Free Cash Flow | 354.90M |
| FCF Per Share | $6.09 |
Margins
| Measure | Value |
|---|
| Gross Margin | 75.42% |
| Operating Margin | 24.03% |
| Pretax Margin | 25.13% |
| Profit Margin | 18.88% |
| EBITDA Margin | 26.67% |
| EBIT Margin | 24.03% |
| FCF Margin | 36.97% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -0.65% |
| Shareholder Yield | -0.65% |
| Earnings Yield | 7.97% |
| FCF Yield | 15.72% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $48.08 |
| Price Target Difference | 24.05% |
| Analyst Consensus | Buy |
| Analyst Count | 12 |
| Revenue Growth Forecast (3Y) | 13.98% |
| EPS Growth Forecast (3Y) | 25.56% |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 5.08 |
| Piotroski F-Score | 5 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |